<DOC>
	<DOCNO>NCT01764828</DOCNO>
	<brief_summary>This open-label , uncontrolled , Phase Ib study design evaluate safety , tolerability , pharmacokinetics BAY86-9766 give single agent combination gemcitabine Asian patient advanced refractory solid tumors.Blood sample PK ( pharmacokinetics ) analysis collect single dose BAY86-9766 , multiple dos BAY86-9766 , combination treatment gemcitabine BAY86-9766 . Safety evaluation include adverse event assessment , vital sign , laboratory test , 12-lead ECG ECG ( electrocardiography ) , cardiac function test , ophthalmologic examination various time point study .</brief_summary>
	<brief_title>BAY86-9766 Plus Gemcitabine Phase I Study Asian</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Male female patient &gt; /= 18 year age , histologically cytologically document advanced refractory solid tumor amenable standard therapy Patients must least one measurable evaluable tumor lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Patients must life expectancy least 12 week , Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) &lt; /=1 . History cardiac disease Active clinically serious infection &gt; Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 Known human immunodeficiency virus ( HIV ) infection Uncontrolled seizure disorder Undergoing renal dialysis Known bleed diathesis History organ allograft Pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety measurement</keyword>
</DOC>